Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab
Open accessAbstract
Dupilumab, the first monoclonal antibody approved by the US Food and Drug Administration for the treatment of moderate-to-severe atopic dermatitis (AD), inhibits interleukin (IL)-4 and IL-13 via blockade of IL-4Ra, inhibiting helper T cell (Th)2 signaling. Allergic contact dermatitis (ACD) has a complex and dynamic pathophysiology, in which at least 1 or more of the Th1, Th2, and Th17/22 pathways may mediate reactions. Patients with AD are at risk of ACD. Here we present a patient with AD and ACD who was patch tested before starting dupilumab and during therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD.
“There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD (eTable).[12][13][14][15][16][17][18][19][20]”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [15]
The Report of case describes significant improvement in one patient’s ACD during dupilumab therapy, so this paper is one relevant report among the cited references. The Discussion calls the benefit potential and says more investigation is necessary; this single case does not establish dupilumab’s effectiveness for ACD generally. (LLM, conf=0.82)
Experimental — accuracy not yet measuredFindings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.
“The findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [15]
The Report of case describes one patient whose dermatitis improved on dupilumab after several treatments failed; he had positive patch tests to nickel and several other allergens. The Discussion describes this as a potential benefit for chronic allergic contact dermatitis, not evidence that dupilumab improves dermatitis caused by a broad range of allergens across patients. Page numbers are not available in the supplied copy. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dhingra, N., Shemer, A., Correa da Rosa, J., Rozenblit, M., Fuentes-Duculan, J., Gittler, J. K., Finney, R., Czarnowicki, T., Zheng, X., Xu, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.009 · Cited by 305 · see citing works
Kitagaki, H., Ono, N., Hayakawa, K., Kitazawa, T., Watanabe, K., & Shiohara, T. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2484 · Cited by 245 · see citing works
Minang, J. T., Troye‐Blomberg, M., Lundeberg, L., & Ahlborg, N. (2005) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2005.01673.x · Cited by 49 · see citing works
Role of IL-4 in delayed type hypersensitivity
Asherson, G. L., Dieli, F., Sireci, G., & Salerno, A. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.845537.x · Cited by 47 · see citing works
Positive patch test reaction in a patient taking dupilumab
Puza, C. J., & Atwater, A. R. (2018) · Dermatitis® · doi:10.1097/der.0000000000000346 · Cited by 31 · see citing works
Patch Testing in a Patient on Dupilumab
Hoot, J. W., Douglas, J. D., & Falo, L. D. (2018) · Dermatitis · doi:10.1097/der.0000000000000357 · Cited by 31 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dupilumab: A Review of Present Indications and Off-Label Uses
Muñoz‐Bellido, F. J., Moreno, E., & Davila, I. J. (2021) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0682 · Cited by 138 · see citing works
Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Olbrich, H., Sadik, C. D., Ludwig, R. J., Thaçi, D., & Boch, K. (2023) · Biomolecules · doi:10.3390/biom13040634 · Cited by 111 · see citing works
A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis
Jaros, J., Hendricks, A. J., Shi, V. Y., & Lio, P. (2020) · Dermatitis · doi:10.1097/der.0000000000000590 · Cited by 47 · see citing works
Patch Testing during Immunosuppressive Therapy: A Systematic Review
Mufti, A., Lu, J. D., Sachdeva, M., Zaaroura, H., Kashetsky, N., Yeung, J., Maibach, H. I., & DeKoven, J. G. (2021) · Dermatitis · doi:10.1097/der.0000000000000726 · Cited by 35 · see citing works
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
The emerging role of dupilumab in dermatological indications
Napolitano, M., Guida, A. D., Nocerino, M., Fabbrocini, G., & Patruno, C. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1907341 · Cited by 20 · see citing works
Bocquel, S., Soria, A., Raison‐Peyron, N., Badaoui, A., Marcant, P., Bara, C., Giordano‐Labadie, F., Amsler, E., Milpied, B., Delaunay, J., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.10.029 · Cited by 18 · see citing works
Virgens, A. R., Góes, H. F. D. O., de Carvalho, G. C., Pietrobon, A. J., Branco, A. C. C. C., Ramos, Y. Á. L., Pereira, N. V., Orfali, R. L., Aoki, V., da Silva, L. F. F., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14442 · Cited by 16 · see citing works
Ophaug, S. L., & Schwarzenberger, K. (2020) · Dermatologic Clinics · doi:10.1016/j.det.2020.02.007 · Cited by 15 · see citing works
Brøgger, P., Blom, L. H., Simonsen, S., Thyssen, J. P., & Skov, L. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12835 · Cited by 14 · see citing works
Shah, P. C., Milam, E. C., Sicco, K. I. L., & Cohen, D. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.05.036 · Cited by 13 · see citing works
Docampo‐Simón, A., Sánchez‐Pujol, M. J., Pastor‐Nieto, M. A., Giménez‐Arnau, A. M., Serna, M. R., Serra‐Baldrich, E., Miquel, J., Sánchez-Pérez, J., Sanz‐Sánchez, T., Zaragoza‐Ninet, V., et al. (2023) · Dermatitis · doi:10.1089/derm.2022.0023 · Cited by 9 · see citing works
T helper 2 inhibitors in allergic contact dermatitis
Ludwig, C. M., Krase, J. M., & Shi, V. Y. (2021) · Dermatitis · doi:10.1097/der.0000000000000616 · Cited by 9 · see citing works
The Importance of Education When Patch Testing
Wu, P. A. (2020) · Dermatologic Clinics · doi:10.1016/j.det.2020.02.004 · Cited by 7 · see citing works
Implication of T Helper Cytokines in Contact Dermatitis and Atopic Dermatitis
Cochez, P. M., Choteau, M., Limaye, N., Baeck, M., & Dumoutier, L. (2020) · Current Treatment Options in Allergy · doi:10.1007/s40521-020-00263-x · Cited by 3 · see citing works
Patch Testing on Dupilumab: Reliable or Not?
Kuzyk, A. C. (2022) · Cutis · doi:10.12788/cutis.0471 · Cited by 3 · see citing works
Toward a Molecular Diagnosis: Looking Under the Skin at Allergic Contact Dermatitis
Bahamon, I., Strassner, J. P., & Ko, W.-C. C. (2023) · Current Dermatology Reports · doi:10.1007/s13671-023-00410-y · Cited by 3 · see citing works
Navarro‐Triviño, F. J., & Ruíz‐Villaverde, R. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.06.010 · Cited by 3 · see citing works
Navarro‐Triviño, F. J., Prados‐Carmona, Á., & Ruíz‐Villaverde, R. (2024) · Medical Reports · doi:10.1016/j.hmedic.2024.100043 · Cited by 1 · see citing works
Navarro‐Triviño, F. J., & Ruíz‐Villaverde, R. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.02.018 · Cited by 1 · see citing works
Hand eczema leaves systemic traces
Roesner, L. M., & Wittmann, M. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad178 · Cited by 1 · see citing works
Bubna, A., & Viplav, V. (2024) · Journal of Skin and Sexually Transmitted Diseases · doi:10.25259/jsstd_45_2024
Bubna, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3791-4_38
- Authors
- Zhu, G. A., Chen, J. K., Chiou, A., Ko, J., & Honari, G.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Honari, Golara
- Venue
- JAAD Case Reports
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 5
- Issue
- 4
- Pages
- 336-338
- ISSN
- 2352-5126 (ISSN-L)
- PMC
- PMC6447730
- OpenAlex
- W2929478233
- Cited by
- 24
- References
- 6
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 1
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JAAD Case Reports (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- allergic contact dermatitis, dupilumab, atopic dermatitis, patch testing, IL-4 receptor alpha blockade, monoclonal antibody therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
